Lead PartnerCrown Bioscience is a cutting edge translational technology company providing drug discovery and preclinical development services in the areas of oncology, immunology, inflammation, cardiovascular, and metabolic disease. We bring clarity to drug discovery and enable clients around the world to deliver superior clinical candidates. Our premier translational platforms for cancer, inflammation, and metabolic disease help our clients accelerate their new drug development programs. www.crownbio.com
INOVOTION is a Contract Research Laboratory implementing a unique approach to in vivo evaluation for anticancer drug discovery. Our cutting-edge proprietary technology provides early analysis of your compounds before the classical preclinical stage. By eliminating low-value molecules early, INOVOTION accelerates your drug discovery process and significantly reduces its costs. INOVOTION has developed a unique technology dedicated to early in vivo EFFICACY and TOXICITY evaluation of anti-cancer drugs.
The Jackson Laboratory
The Jackson Laboratory is a leading provider of cancer mouse models and in vivo oncology services and a National Cancer Institute designated Cancer Center. Drawing on decades of research experience we provide capabilities around model selection, husbandry and customisable oncology studies to help clients and researchers evaluate novel anti-cancer therapies. Our diverse oncology study protocols range from traditional xenograft services to PDX cancer models and advanced humanised mouse models for immuno-oncology drug development.
Hera Biolabs, Inc., is an innovative pre-clinical CRO utilising cutting edge gene editing technologies to create novel in vivo models for oncology. Given our mission to accelerate cancer research and drug development, we focus upon rat models to deliver translationally relevant, high-quality results using proprietary technologies. Our first SRG model is the OncoRat®, which is uniquely suited for xenograft studies given its excellent tumour take-rates and ability to deliver masses 10x that of mouse models in half the time – all without the increased risk of genetic drift from multiple passages as observed in mice.
GenOway specialises in genetic designs to serve genetically modified (GM) mice, rat and cell lines of highest standards for academic and biopharmaceutical research, and has created more than 2000 GM models, while serving clients in:
• 28 countries worldwide
• 380 academic institutions and 13 EU projects
• 170 Life Sciences companies
• 15 of the Top 20 pharma
MI Bioresearch (MI), a preclinical oncology service provider, offers in vitro services, oncology pharmacology, in vivo imaging, and focal radiation to support research programs. Our team explores the effects of your drugs and biologics using both human and syngeneic models and multi-modality imaging systems. MI provides you with decision driving data to help advance your drug candidate toward the next cancer research breakthrough. One Focus. One Purpose. Oncology Research.
Mi-mAbs is an innovative integrated immunotechnology center designed to accelerate the development of new immunotherapy antibodies against cancer and inflammatory diseases. Open to the best targets of academic and industrial research, MI-mAbs determines their expression profile, generates antibodies and validates them.
MI-mAbs, a multi-disciplinary team, involving experts in hybridoma, in molecular biology, biochemistry, immunochemistry , anatomopathology and in vitro/in vivo immunopharmacology has an objective to be the 1st integrated platform that generates and validates therapeutic antibodies in Cancerology and Inflammation. MI-mAbs contracts with research institutions, public technology transfer offices, or biotech companies
ProQinase GmbH was founded in 2001 as a subsidiary of the Tumor Biology Center Freiburg. This cancer center combined excellent research with exceptional patient care under one roof. Initially, ProQinase was established in order to support funding of the Tumor Biology Center´s in-house anti-cancer drug development by marketing research tools and test systems. Today, ProQinase is a leading contract research organization (CRO) for drug discovery in oncology. In February 2019 ProQinase was purchased by Reaction Biology Corporation located in Malvern, PA. RBC is a leader in early stage drug-discovery services, with a heavy focus on kinase and epigenetic drug targets for both biochemical and cell-based assays. The combination of RBC and ProQinase
Repositive is a technology company with the mission to increase discovery, access and sharing of genomic data for the benefit of patients. In 2017 we initiated a collaboration with leading biopharma organisations and CROs to launch the Cancer Models Platform to act as a market place of translational oncology models and a network for oncology researchers. The platform incorporates PDX, CDX, syngeneic and humanised mouse models, 3D in vitro systems and other popular translational cancer models. Our vision is becoming the largest catalogue of commercially available oncology models.
VIVOPHARM, a CGI company (NASDAQ:CGIX), is a successful and fast-growing precision contract research organisation (CRO) providing integrated preclinical services from bench to bedside worldwide. We use our experience and expertise to assist in the planning of and conducting tailored studies, from discovery stages through to clinical.
Champions Oncology was founded by renowned specialists in the field of cancer diagnosis, treatment, and research. The Champions Oncology team is comprised of seasoned oncology professionals passionately dedicated to working to accelerate oncology drug development, improve treatment outcomes and extend lives. Our core platform, the Champions TumorGraft™ offers an enhanced xenograft mouse avatar.
Imagen Therapeutics specialises in developing clinically relevant 2/3D primary cell models for both cancer patients and the BioPharma industry. Through accurate phenotypic drug sensitivity testing, oncologists are able to personalise treatment strategies for patients, and BioPharma are able to select cell models of their choice for pre-clinical and translational research. Imagen have aspirations to build the world’s leading low passage, clinically relevant, living primary cell model BioBank, with matched patient blood samples, full clinical annotation and NGS.